细胞免疫治疗的前景与挑战

Cellular immunotherapy： Prospects and Challenges

以树突状细胞（dendritic cells，DC）为代表的细胞免疫治疗因具有恢复免疫平衡和消灭肿瘤干细胞的潜在优势，有望在治愈肿瘤方面发挥重要作用。世界上第一个治疗性DC疫苗已被美国FDA批准应用。但是，大部分DC疫苗虽然体外及动物实验结果良好，但临床疗效欠佳、异质性大。本文就DC免疫治疗的优势、已经取得的成果和面临的挑战作一综述。

Cellular immunotherapy, represented by dendritic cell （DC）, is capable of eradicating cancer stem cells and restoring the homeostasis imbalance, therefore has emerged as a promising approach to cure tumor. The first therapeutic DC vaccine on earth has been approved by FDA of America. However, the satisfactory therapeutic benefits of DC vaccine observed in vivo （animal） studies could barely be recapitulated in clinical settings. This article reviews the advantages of DC immunotherapy, achievements had been made and challenges have to confront.